[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594490":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":25,"locations":31,"responsibleParty":173,"collaborators":11,"id":175,"slug":176,"hasResults":177,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":11,"eligibilityCriteria":181,"healthyVolunteers":177,"sex":182,"minAge":183,"maxAge":11,"enrollmentInfo":184,"targetDuration":11,"studyType":187,"phases":188,"briefSummary":190,"conditions":191,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":208},{"fullName":5,"class":6},"Aktis Oncology, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[225Ac]Ac-AKY-1189","EXPERIMENTAL",null,[13,14],"Drug: [225Ac]Ac-AKY-1189 (therapeutic)","Drug: [64Cu]Cu-AKY-1189 (imaging)",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","[225Ac]Ac-AKY-1189 (therapeutic)","\\[225Ac\\]Ac-AKY-1189 Injection",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"[64Cu]Cu-AKY-1189 (imaging)","\\[64Cu\\]Cu-AKY-1189 Injection",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Janet Horton, MD","CONTACT","978-208-3986","AKY-1189-01inquiries@aktisoncology.com",[32,51,65,80,97,112,126,143,158],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-117.97729,34.13945,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":49,"phoneExt":11,"email":50},"Abhishek Tripathi, MD","626-256-4673","atripathi@coh.org",{"facility":52,"status":34,"city":53,"state":36,"zip":54,"country":38,"countryCode":39,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Hoag Memorial Hospital Presbyterian","Irvine","92618",{"type":41,"coordinates":56},[57,58],-117.82311,33.66946,{"lat":58,"lon":57},[61],{"name":62,"role":28,"phone":63,"phoneExt":11,"email":64},"Ryan Reddy, MD","949-764-4577","ryan.reddy@hoag.org",{"facility":66,"status":34,"city":67,"state":68,"zip":69,"country":38,"countryCode":39,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Biogenix Molecular, LLC","Miami","Florida","33165",{"type":41,"coordinates":71},[72,73],-80.19366,25.77427,{"lat":73,"lon":72},[76],{"name":77,"role":28,"phone":78,"phoneExt":11,"email":79},"Jerry Joseph","786-791-1799","jjoseph@cira-health.com",{"facility":81,"status":34,"city":82,"state":83,"zip":84,"country":38,"countryCode":39,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"University of Iowa","Iowa City","Iowa","52242",{"type":41,"coordinates":86},[87,88],-91.53017,41.66113,{"lat":88,"lon":87},[91,95],{"name":92,"role":28,"phone":93,"phoneExt":11,"email":94},"Kristin West","319-356-3656","kristin-gaimari-varner@uiowa.edu",{"name":96,"role":28,"phone":11,"phoneExt":11,"email":11},"Kristin Plichta, MD, PhD",{"facility":98,"status":34,"city":99,"state":100,"zip":101,"country":38,"countryCode":39,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"United Theranostics","Glen Burnie","Maryland","21061",{"type":41,"coordinates":103},[104,105],-76.62469,39.16261,{"lat":105,"lon":104},[108],{"name":109,"role":28,"phone":110,"phoneExt":11,"email":111},"Amanda Huggins","667-467-3669","clinicaltrial@unithera.com",{"facility":113,"status":34,"city":114,"state":115,"zip":116,"country":38,"countryCode":39,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"BAMF Health","Grand Rapids","Michigan","49503",{"type":41,"coordinates":118},[119,120],-85.66809,42.96336,{"lat":120,"lon":119},[123],{"name":11,"role":28,"phone":124,"phoneExt":11,"email":125},"616-330-2735","ResearchClinicalTeam@bamfhealth.com",{"facility":127,"status":34,"city":128,"state":128,"zip":129,"country":38,"countryCode":39,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Icahn School of Medicine at Mt. Sinai","New York","10029",{"type":41,"coordinates":131},[132,133],-74.00597,40.71427,{"lat":133,"lon":132},[136,140],{"name":137,"role":28,"phone":138,"phoneExt":11,"email":139},"Sophia Rhoads","317-903-4419","Sophia.rhoads@mssm.edu",{"name":141,"role":28,"phone":11,"phoneExt":11,"email":142},"Patricia Acon","patricia.acon@mssm.edu",{"facility":144,"status":34,"city":145,"state":146,"zip":147,"country":38,"countryCode":39,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"UPMC","Pittsburgh","Pennsylvania","15232",{"type":41,"coordinates":149},[150,151],-79.99589,40.44062,{"lat":151,"lon":150},[154],{"name":155,"role":28,"phone":156,"phoneExt":11,"email":157},"Samantha Demko, RN, BSN","412-623-1400","albesl@upmc.edu",{"facility":159,"status":34,"city":160,"state":161,"zip":162,"country":38,"countryCode":39,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":41,"coordinates":164},[165,166],-95.36327,29.76328,{"lat":166,"lon":165},[169],{"name":170,"role":28,"phone":171,"phoneExt":11,"email":172},"Natalie Velez","713-792-1478","navelez@mdanderson.org",{"type":174,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100594490","phase-1-a-study-of-225acac-aky-1189-in-patients-with-solid-tumors-100594490",false,"NCT07020117","A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors","NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Histologic or cytologic confirmation of locally advance or metastatic disease\n* Radiologic confirmation on CT of at least one measurable tumor lesion per RECIST v1.1\n* ECOG Performance Status of 0 or 1\n* Adequate end-organ function\n* Ability to give informed consent and comply with study requirements\n* Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids\n* Documented disease progression on prior line of therapy for metastatic disease\n\nExclusion Criteria:\n\n* Prior treatment with a therapeutic radiopharmaceutical\n* Prior treatment with a Nectin-4 targeted therapy, except enfortumab vedotin\n* Received an investigational agent within the previous 28days\n* Prior treatment with a cytotoxic chemotherapy, targeted therapy, biologic agent, immunotherapy or external-beam radiotherapy in the 3 weeks prior to study treatment\n* Concurrent serious medical condition that would impair study participation or impact the assessment of treatment related toxicity","ALL","18 Years",{"count":185,"type":186},150,"ESTIMATED","INTERVENTIONAL",[189],"PHASE1","This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\\[225Ac\\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.",[192,193,194,195,196,197,198],"Urothelial Carcinoma Bladder","Triple Negative Breast Cancer (TNBC)","Hormone Receptor Positive Breast Adenocarcinoma","Non Small Cell Lung Cancer","Cervical Adenocarcinoma","Colorectal Adenocarcinoma","Head and Neck Cancer","2026-04-17",{"date":201,"type":202},"2026-04-21","ACTUAL",{"date":204,"type":202},"2025-08-22",{"date":206,"type":186},"2032-06",{"name":5,"class":6},9]